Proposal to amend listing in the National Immunisation Schedule – meningococcal C conjugate vaccine

In summary, the proposal would result in:

• Neisvac-C(external link) remaining as the only listed meningococcal C conjugate vaccine on the National Immunisation Schedule.
  • the delisting of Neisvac-C in the 10 injection pack presentation.
  • a correction of the chemical name for Neisvac-C in the Pharmaceutical Schedule.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5 pm Wednesday, 7 June 2017 to:

Matthew Wolfenden
Procurement Manager
PHARMAC

Email: vaccines@pharmac.govt.nz

Fax:     04 460 4995
Post:   PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

Details of the proposal

PHARMAC proposes that from 1 July 2017 Neisvac-C would remain listed in Section I (the National Immunisation Schedule) and Part II Section H of the Pharmaceutical Schedule:

• with a correction to the chemical name;
• as a single injection pack size; and
• the 10 injection pack size would be delisted from 1 July 2017

as follows (additions in bold deletions in strikethrough):

There would be no changes to the current restrictions in Section I or Part II of Section H of the Pharmaceutical Schedule which are: